Genprex Inc. Receives Orphan Drug Designation For Immunogene Therapy For Treatment Of SCLC
Portfolio Pulse from Happy Mohamed
Genprex Inc. (NASDAQ:GNPX) has been granted FDA orphan drug designation for its REQORSA immunogene therapy in development for the treatment of small cell lung cancer (SCLC). The Orphan Drug Designation (ODD) is intended to spark innovation among biotech companies by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval.
September 21, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genprex's FDA orphan drug designation for its REQORSA immunogene therapy could provide the company with significant incentives and market exclusivity, potentially boosting its stock in the short term.
The FDA's orphan drug designation is a significant milestone for biotech companies as it provides incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. This could potentially lead to increased investor interest in Genprex, driving up its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100